These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35587448)

  • 1. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
    Cuff H; Lord K; Ballester L; Scully T; Stewart N; De Leon DD
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3115-e3120. PubMed ID: 35587448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.
    Shah P; Rahman SA; McElroy S; Gilbert C; Morgan K; Hinchey L; Senniappan S; Levy H; Amin R; Hussain K
    Horm Res Paediatr; 2015; 84(5):355-60. PubMed ID: 26375451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.
    Dastamani A; Güemes M; Pitfield C; Morgan K; Rajab M; Rottenburger C; Bomanji J; De Coppi P; Dattani M; Shah P
    Horm Res Paediatr; 2019; 91(1):56-61. PubMed ID: 30114684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
    Novokreshhennyx EE; Gubaeva DN; Melikyan MA
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):70-78. PubMed ID: 33369374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.
    Juliana CA; Chai J; Arroyo P; Rico-Bautista E; Betz SF; De León DD
    J Biol Chem; 2023 Jun; 299(6):104816. PubMed ID: 37178920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
    Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Hypoglycemia Phenotype in Congenital Hyperinsulinism Due to Dominant Mutations of Uncoupling Protein 2.
    Ferrara CT; Boodhansingh KE; Paradies E; Fiermonte G; Steinkrauss LJ; Topor LS; Quintos JB; Ganguly A; De Leon DD; Palmieri F; Stanley CA
    J Clin Endocrinol Metab; 2017 Mar; 102(3):942-949. PubMed ID: 27967291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
    van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
    Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.
    Peterson SM; Juliana CA; Hu CF; Chai J; Holliday C; Chan KY; Lujan Hernandez AG; Challocombe Z; Wang L; Han Z; Haas N; Stafford R; Axelrod F; Yuan TZ; De León DD; Sato AK
    Diabetes; 2023 Sep; 72(9):1320-1329. PubMed ID: 37358194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
    Modan-Moses D; Koren I; Mazor-Aronovitch K; Pinhas-Hamiel O; Landau H
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2312-7. PubMed ID: 21697252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
    Kühnen P; Marquard J; Ernert A; Meissner T; Raile K; Wannenmacher G; Blankenstein O
    Horm Res Paediatr; 2012; 78(2):106-12. PubMed ID: 22907123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
    Giri D; Price V; Yung Z; Didi M; Senniappan S
    J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):347-50. PubMed ID: 27087264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperinsulinism in the Neonate.
    Lord K; De León DD
    Clin Perinatol; 2018 Mar; 45(1):61-74. PubMed ID: 29406007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic characteristics of patients with congenital hyperinsulinism.
    Vajravelu ME; De León DD
    Curr Opin Pediatr; 2018 Aug; 30(4):568-575. PubMed ID: 29750770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.
    Calabria AC; Li C; Gallagher PR; Stanley CA; De León DD
    Diabetes; 2012 Oct; 61(10):2585-91. PubMed ID: 22855730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.
    Katz LE; Ferry RJ; Stanley CA; Collett-Solberg PF; Baker L; Cohen P
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3117-24. PubMed ID: 10487673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.